文献速递艾滋病与性传播感染

巴拿马儿童和青少年HIV感染者的耐药情况

Drug resistance in children and adolescents with HIV in Panama.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

接受治疗且病毒学失败者中54.8%携带耐药株,以NRTI和NNRTI耐药为主,作者认为应常规开展耐药监测以优化挽救治疗选择。

要点

  • 67例获得HIV-1 pol序列的儿童/青少年中,接受治疗且病毒学失败者54.8%携带耐药株。
  • 耐药以NRTI(58.5%)和NNRTI(39%)为主,PI和INSTI主要耐药突变分别占4.9%和6.5%。
  • 作者认为巴拿马治疗儿童/青少年NRTI和NNRTI耐药率高,应常规开展耐药监测以优化挽救治疗。

核心结论

  • 巴拿马接受治疗的HIV感染儿童/青少年中NRTI和NNRTI耐药突变流行率高,作者认为应常规开展耐药监测以优化该脆弱人群的挽救治疗选择。

主要发现

  • 76例儿童/青少年中67例(88.2%)获得HIV-1 pol序列,中位年龄12岁,携带65例B亚型、1例G亚型和1例独特重组型URF_A1B。
  • 5例未治疗,62例已治疗且病毒学失败(病毒血症>50拷贝/mL),既往暴露于NRTI(100%)、NNRTI(45.2%)、PI(95.2%)和整合酶链转移抑制剂(INSTI,17.7%)。
  • 已治疗患者中34例(54.8%)携带耐药株,对1个(40.3%)、2个(9.7%)或3个(4.8%)抗逆转录病毒药物家族存在主要耐药突变。
  • 多数携带NRTI(58.5%)或NNRTI(39%)耐药突变,也有PI(4.9%)和INSTI(6.5%)主要耐药突变;发现NRTI+NNRTI双重耐药(12.2%)和NNRTI+PI耐药(2.6%)。
  • 2例未治疗者分别携带NRTI耐药突变和NRTI+NNRTI耐药突变的病毒;测序病毒主要对恩曲他滨/拉米夫定(各48.9%)和依非韦伦/奈韦拉平(各33.3%)呈高度/中度耐药,多数对PI(91.3%)和INSTI(88.1%)敏感。

临床怎么用

  • 作者认为巴拿马治疗儿童/青少年NRTI和NNRTI耐药率高,应常规开展耐药监测以优化挽救治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The inadequacy of resistance monitoring in Latin America leads to circulation of HIV strains with drug resistance mutations (DRMs), compromising ART effectiveness. This study describes the DRM prevalence in HIV-infected paediatric patients in Panama. METHODS: During 2018-19, plasma was collected from 76 HIV-infected children/adolescents (5 ART-naive, 71 treated) in Panama for HIV-1 DRM pol analysis, predicted antiretroviral (ARV) susceptibility by Stanford, and HIV-1 variant phylogenetic characterization. RESULTS: HIV-1 pol sequences were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years), carrying 65 subtype B, 1 subtype G and 1 unique recombinant URF_A1B. Five were ART-naive and 62 ART-treated under virological failure (viraemia >50 copies/mL) with previous exposure to NRTIs, (100%), NNRTIs (45.2%), PIs (95.2%) and integrase strand transfer inhibitors (INSTIs, 17.7%). Among the treated patients, 34 (54.8%) carried resistant strains, with major DRMs to one (40.3%), two (9.7%) or three (4.8%) ARV families. Most of them harboured DRMs to NRTIs (58.5%) or NNRTIs (39%), but also major DRMs to PIs (4.9%) and INSTIs (6.5%). We also found dual-class NRTI + NNRTI (12.2%) and NNRTI + PI (2.6%) resistance. Two naive subjects carried viruses with DRMs to NRTIs and NRTI + NNRTI, respectively. Sequenced viruses presented high/intermediate resistance mainly to emtricitabine/lamivudine (48.9% each) and efavirenz/nevirapine (33.3% each). Most participants were susceptible to PIs (91.3%) and INSTIs (88.1%). CONCLUSIONS: The high DRM prevalence to NRTIs and NNRTIs observed among treated HIV-infected children/adolescents in Panama justifies the need for routine resistance monitoring for optimal rescue therapy selection in this vulnerable population.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ventosa-Cubillo J, Pinzón R, González-Alba JM, et al. Drug resistance in children and adolescents with HIV in Panama. J Antimicrob Chemother. 2023. PMID: 36454248. doi:10.1093/jac/dkac407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。